$LLY

Eli Lilly received FDA approval for Foundayo weight-loss pill in April 2026. With 40%+ growth and premium valuation, stock needs only 20% gain to hit $1 trillion market cap.

$LLY surged 1,100% in ten years via GLP-1 drugs, but 39x P/E ratio and patent risks loom.

Amazon acquires Globalstar for $11.6B to expand satellite internet; Instacart buys Instaleap; QVC files bankruptcy with $5B debt.

Kailera Therapeutics raised $625M in largest biotech IPO since 2021, entering competitive obesity market with oral GLP-1 candidate showing 12.1% weight loss.

Eli Lilly's obesity pill logged 1,390 first-week prescriptions versus Novo Nordisk's 3,071 in four days, as $NVO maintains commanding 113,354 weekly Wegovy prescriptions.

China's diabetes device market projected to nearly double from $7.19B in 2025 to $14.51B by 2034, driven by 118M patients and healthcare reforms.

$VKING develops competing obesity drugs against $LLY and $NVO, with oral candidate entering phase 3 trials in Q3 2026 amid projected $100B market expansion.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.

MeiraGTx reacquires J&J's eye disease drug bota-vec for $25M, raises $100M in funding, targeting 2027 launch. Stock falls 15.8%.

Eli Lilly acquires Centessa Pharmaceuticals for $6.3B, gaining neuroscience assets. Stock rises on strong financial footing from weight-loss drug success.

Eli Lilly's oral weight loss drug Foundayo met cardiovascular safety goals in Phase 3 trials, showing 57% lower mortality risk versus insulin. FDA filing planned for Q2 2026.

Eli Lilly controls 60% of U.S. weight loss market with $11B+ quarterly revenue. Pipeline drug retatrutide showing 28% weight reduction could extend lead over Novo Nordisk.

Eli Lilly reaches $1 trillion valuation while outperforming Novo Nordisk over three years, driven by superior weight-loss drug efficacy and robust pipeline strength.

GoodRx shares rose 2.69% as the platform expands access to Novo Nordisk's Wegovy HD at $399/month, capitalizing on the surging self-pay GLP-1 obesity treatment market.

Eli Lilly reports fourth positive Phase 3 trial for Jaypirca in chronic lymphocytic leukemia, positioning drug for label expansion ahead of competitive launches.

Global dementia market expanding rapidly as disease-modifying treatments like LEQEMBI and KISUNLA shift focus from symptom management to early intervention for 55 million affected patients worldwide.

S&P 500 index investing offers low-cost diversification with proven resilience, outperforming active trading through disciplined, long-term holding.

Atopic dermatitis drug market projected to grow from $8.5B (2023) to $21.5B (2033) at 9.8% CAGR, fueled by seven late-stage pipeline therapies.

Global atopic dermatitis market projected to grow from $10.8B in 2023 to $26.2B by 2033, driven by seven late-stage pipeline drugs and expanded treatment options.

Crohn's Disease drug market projected to grow 45% to $13.8B by 2032, driven by eight new therapies with novel mechanisms of action reshaping competition.